title: Human T lymphotropic virus types I and II western blot seroindeterminate status and its association with exposure to prototype HTLV-I.
abstract: Human T lymphotropic virus types I and II (HTLV-I/II) Western blot (WB) seroindeterminate status, which is defined as an incomplete banding pattern of HTLV protein Gag (p19 or p24) or Env (GD21 or rgp46), is commonly observed. To investigate the significance of this finding, we examined HTLV-I/II serostatus and HTLV-I proviral load in 2 groups of individuals with WB seroindeterminate status. Low proviral loads were detected in 42% of patients with neurologic symptoms and 44% of voluntary blood donors. These data suggest that a subset of WB seroindeterminate individuals may be infected with prototype HTLV-I. To confirm this hypothesis, we evaluated HTLV-I/II serostatus and proviral load in prospectively collected specimens from 66 WB seronegative patients who had received HTLV-I-infected blood products by transfusion. Eight individuals developed WB seroindeterminate profiles after the transfusion. In addition, using a human leukocyte antigen type A*201-restricted HTLV-I Tax11-19 tetramer, we detected virus-specific CD8(+) T cells in peripheral blood mononuclear cells from WB seroindeterminate patients. These CD8(+) T cells were effective at targeting HTLV-I-infected cells. Collectively, the results suggest that HTLV-I/II WB seroindeterminate status may reflect a history of HTLV-I exposure. Our findings warrant further investigation of the possible clinical outcomes associated with WB seroindeterminate status.
authors.affiliation: Viral Immunology Section, Neuroimmunology Branch, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Karen
authors.initials: K
authors.lastname: Yao
authors.forename: Michie
authors.initials: M
authors.lastname: Hisada
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Maloney
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Yamano
authors.forename: Barrie
authors.initials: B
authors.lastname: Hanchard
authors.forename: Rainford
authors.initials: R
authors.lastname: Wilks
authors.forename: Maria
authors.initials: M
authors.lastname: Rios
authors.forename: Steven
authors.initials: S
authors.lastname: Jacobson
mesh_terms: D001782:Blood Donors; D015153:Blotting, Western; D004279:DNA, Viral / Q000097:blood; D015481:HTLV-I Antibodies / Q000097:blood*; D015490:HTLV-I Infections / Q000453:epidemiology / Q000276:immunology* / Q000821:virology; D015482:HTLV-II Antibodies / Q000097:blood*; D015491:HTLV-II Infections / Q000453:epidemiology / Q000276:immunology / Q000821:virology; D015368:Human T-lymphotropic virus 1 / Q000145:classification* / Q000276:immunology; D015367:Human T-lymphotropic virus 2 / Q000145:classification* / Q000276:immunology; D006801:Humans; D009422:Nervous System Diseases / Q000453:epidemiology / Q000276:immunology / Q000821:virology; D011533:Proviruses / Q000302:isolation & purification; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D065227:Transfusion Reaction; D019562:Viral Load
chemical_list: D004279:DNA, Viral; D015481:HTLV-I Antibodies; D015482:HTLV-II Antibodies